CTXR · Citius Pharmaceuticals, Inc.

Citius Oncology reported robust early commercial execution for LYMPHIR™, its FDA-approved treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The launch metrics demonstrate strong institutional uptake, with 83% of target accounts having added or actively progressing the drug through formulary review. Market access efforts have secured coverage under approximately 135 health plans, representing roughly 80% of covered lives, with no reported reimbursement denials or prior authorization barriers to date. This broad payer coverage is critical for facilitating patient access and supporting prescribing momentum. The company noted sequential growth in orders since launch, with initial accounts already placing repeat orders, which suggests early prescribing continuity and product acceptance. Commercial buildout is proceeding with field team onboarding and expansion into community infusion centers, which broadens the addressable patient base beyond major cancer centers. Concurrently, clinical development is advancing through academic collaborations. Positive topline data from a University of Minnesota investigator-sponsored study evaluating LYMPHIR prior to CAR-T therapy was presented at the ASTCT 2026 Annual Meeting. Additionally, a Phase I study at UPMC evaluating LYMPHIR in combination with pembrolizumab in solid tumors has been completed with positive results submitted for presentation. These studies support the strategic evaluation of LYMPHIR as a potential combination therapy in broader immuno-oncology settings. Management estimates the initial market opportunity exceeds $400 million, supported by orphan drug designation and intellectual property protections.